Molecular docking analysis of pyrrole derivatives with the human epidermal growth factor receptor 2: Combating breast...

Area of Science:

• Oncology
• Pharmacology
• Computational Chemistry

Background:

• Breast cancer is a heterogeneous disease and a leading cause of cancer death in women.
• The human epidermal growth factor receptor 2 (HER2) is a key target in breast cancer therapy.
• Synthetic compounds are being explored for novel anti-cancer activities.

Purpose of the Study:

• To virtually screen the synthetic pyrrole derivative SR9009 against the HER2 target protein.
• To evaluate the binding affinity and energy of SR9009 with HER2 using computational methods.
• To assess the potential of SR9009 as a clinical candidate for anti-breast cancer therapy.

Main Methods:

• Virtual screening using molecular docking.
• Molecular Dynamics simulations to calculate binding energy.
• Comparison of SR9009 binding with Trastuzumab, a known HER2 inhibitor.

Main Results:

• Molecular docking revealed higher binding affinity of SR9009 to the HER2 protein.
• Molecular Dynamics simulations showed SR9009 has a higher binding energy (-158.436 +/- 11.495 kJ/mol) compared to Trastuzumab (-134.772 +/- 19.859 kJ/mol) for the HER2 complex.
• SR9009 demonstrated significant cytotoxic activity.

Conclusions:

• SR9009 exhibits promising anti-breast cancer activity by targeting HER2.
• Computational studies suggest SR9009 is a potential clinical candidate for HER2-positive breast cancer.
• Further research is warranted to explore SR9009's therapeutic efficacy and safety.